338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

• Sung-Bae Kim,
• Jennifer Yearley,
• Rebecca Dent,
• Javier Cortes,
• Lingkang Huang,
• Yeon Hee Park,
• Theodoros Foukakis,
• Eva Muñoz-Couselo,
• Yuan Sun,
• Peter Schmid,
• Joohyuk Sohn,
• Seock-Ah Im,
• Esther Holgado,
• Sherko Kümmel,
• Petar Jelinic,
• Vassiliki Karantza

Affiliations

Sung-Bae Kim

8Asan Medical Center, Seoul, Korea, Republic of

Jennifer Yearley

Aff244 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA

Rebecca Dent

3Department of Medical Oncology, National Cancer Centre, Singapore, Singapore

Javier Cortes

2Private Practice

Lingkang Huang

3 Merck & Co., Inc, Kenilworth, New Jersey, USA

Yeon Hee Park

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Theodoros Foukakis

Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden

Eva Muñoz-Couselo

Oncology Department, Vall d’Hebron Hospital Universitari, Barcelona, Catalunya, Spain

Yuan Sun

Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Peter Schmid

1Centre for Experimental Cancer Medicine, London, UK

Joohyuk Sohn

5Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of

Seock-Ah Im

6Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of

Esther Holgado

7Ramón y Cajal University, Madrid, Spain

Sherko Kümmel

9Kliniken Essen-Mitte, Essen, Germany

Petar Jelinic

11Merck and Co., Inc., Kenilworth, NJ, USA

Vassiliki Karantza

11Merck and Co., Inc., Kenilworth, NJ, USA